These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. [Antiphospholipid syndrome and changes in the eye]. Gerkowicz M; Latalska M; Kosior-Jarecka E; Kozioł-Montewka M; Pietraś-Trzpiel M Klin Oczna; 2005; 107(1-3):143-6. PubMed ID: 16052828 [TBL] [Abstract][Full Text] [Related]
7. [Methods of prevention of ischemic cerebral damages in patients with antiphospholipid antibodies]. Roşca T Oftalmologia; 2008; 52(2):72-6. PubMed ID: 19065918 [TBL] [Abstract][Full Text] [Related]
8. Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome. Sanmarco M; Boffa MC Lupus; 2009 Sep; 18(10):920-3. PubMed ID: 19671793 [TBL] [Abstract][Full Text] [Related]
9. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. Girón-González JA; García del Río E; Rodríguez C; Rodríguez-Martorell J; Serrano A J Rheumatol; 2004 Aug; 31(8):1560-7. PubMed ID: 15290736 [TBL] [Abstract][Full Text] [Related]
10. Antiphospholipid antibodies bind to activated but not resting endothelial cells: is an independent triggering event required to induce antiphospholipid antibody-mediated disease? Chen Q; Stone PR; Woon ST; Ching LM; Hung S; McCowan LM; Chamley LW Thromb Res; 2004; 114(2):101-11. PubMed ID: 15306152 [TBL] [Abstract][Full Text] [Related]
11. Revisiting antiphospholipid antibodies: from targeting phospholipids to phospholipid binding proteins. Bertolaccini ML; Hughes GR; Khamashta MA Clin Lab; 2004; 50(11-12):653-65. PubMed ID: 15575307 [TBL] [Abstract][Full Text] [Related]
16. Need for additional trials of primary prophylaxis in patients with high-risk antiphospholipid antibody profiles: comment on the article by Erkan et al. Wahl D; Lecompte T; Bounameaux H Arthritis Rheum; 2008 Feb; 58(2):635-6; author reply 636. PubMed ID: 18240250 [No Abstract] [Full Text] [Related]
17. Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study. Ruffatti A; Del Ross T; Ciprian M; Nuzzo M; Rampudda M; Bertero MT; Bergia R; Caramaschi P; Biasi D; Capsoni F; Montaguti L; Ruffini R; Brucato A; Picillo U; Fanelli V; Riccieri V; Piccoli A; Valesini G; Doria A; Meroni PL; Tincani A Ann Rheum Dis; 2009 Mar; 68(3):397-9. PubMed ID: 18812393 [TBL] [Abstract][Full Text] [Related]
18. [Antiphospholipid antibodies with HCV infection. Innocent proteins or risk factor?]. Kisiel E; Kryczka W Przegl Lek; 2007; 64(7-8):521-4. PubMed ID: 18409357 [TBL] [Abstract][Full Text] [Related]
19. Clinical performance (sensitivity and agreement with thrombosis) of four antiphospholipid antibody assays. Lopez LR; Whittier AM; Dier KJ; Taylor DO; Buckner TR; Olsen LW; Fink CA Am Clin Lab; 2002 Apr; 21(3):41-4. PubMed ID: 12038085 [No Abstract] [Full Text] [Related]
20. Is there an association between complement activation and antiphospholipid antibody-related thrombosis? Devreese KM; Hoylaerts MF Thromb Haemost; 2010 Dec; 104(6):1279-81. PubMed ID: 20838748 [No Abstract] [Full Text] [Related] [Next] [New Search]